Search
Wanbangde Receives Approval for Clinical Trial Application of Huperzine A Oral Solution
2025-04-29 /
Read about 0 minute
Author：小编
Wanbangde has announced that the National Medical Products Administration has accepted the application for a clinical trial of Huperzine A Oral Solution, a drug developed by its wholly-owned subsidiary, Wanbangde Pharmaceutical Group, for the treatment of myasthenia gravis. This medication boasts high activity and selectivity as a cholinesterase inhibitor.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
